Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products
Federal officials say that some of the money changing hands has corrupted doctors and endangered patients.
Drugs
501 - 520 of 1,305 Results
-
-
KHN鈥檚 鈥榃hat the Health?鈥: Our 200th Episode!
The federal approval of a controversial drug to treat Alzheimer鈥檚 disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast鈥檚 200th episode, the panelists discuss what has surprised them most and least over the past four years.
-
Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say
Safety-net clinics especially are bracing for how the drugmaker鈥檚 policy shift could reduce their budgets and hamstring their ability to provide care to an at-risk population.
-
Unused Johnson & Johnson Covid Doses Are Piling Up as FDA Waits to See if Shelf Life Can Be Extended
As vaccine expiration dates loom, states with hundreds of thousands of doses on hand say demand is tanking and there鈥檚 no easy way to donate to other states or countries that might want them
By Rachana Pradhan and Christina Jewett -
FDA Weighs Approval of a Lucrative Alzheimer鈥檚 Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen鈥檚 drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
By Harris Meyer -
KHN鈥檚 鈥榃hat the Health?鈥: The Drug Price Dilemma
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it鈥檚 hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss the prospects for policy changes.
-
KHN Journalist Combs for Clues on Covid’s Origins
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
Biden Administration Signals It鈥檚 in No Rush to Allow Canadian Drug Imports
Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it鈥檚 unclear when or if the FDA would approve any state鈥檚 importation plan.
-
Opioids Like 鈥楲ean鈥 Permeate Hip-Hop Culture, but Dangers Are Downplayed
In big cities and small towns, opioid use among some young hip-hop fans is about emulating their favorite rap star鈥檚 image 鈥 while paying little attention to the serious consequences.
-
KHN鈥檚 鈥榃hat the Health?鈥: The Return of the Public Option
Lawmakers are working on fleshing out the concept of a 鈥減ublic option,鈥 a government-run or heavily regulated insurance plan that would compete with private insurance. But the details are complicated, both substantively and politically. Meanwhile, bioethicists are debating whether the U.S. should be vaccinating low-risk adolescents against covid-19 while high-risk adults in other countries are still waiting. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Rachana Pradhan of KHN join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Colorado Lawmakers Wage Multifront Assault on High Drug Costs
Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.
-
KHN Journalists Comment on Abortion Case, Wasted Covid Doses
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
KHN鈥檚 鈥榃hat the Health?鈥: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more.
-
From Covid Coverage to ‘Public Option’ Plans, Journalists Delve Into Details
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
This Small Canadian Drugmaker Wants to Make J&J Vaccines for Poor Nations. It Needs More Than a Patent Waiver.
All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.
By Sarah Jane Tribble and Arthur Allen -
KHN鈥檚 鈥榃hat the Health?鈥: Sharing Vaccines With the World
The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Covid Shot in the Arm Not Enough to Keep Pharmacies in Business
Pandemic lockdowns exacerbated long-standing economic pressures on pharmacies 鈥 and forced many owner-operated shops to evolve or risk closing their doors.
-
Democrats Disagree About How to Spend Potential Prescription Drug Windfall
After a year of uncharacteristically being on the same page when it comes to health care, Democratic lawmakers are at loggerheads about what to do next. Most agree the time is ripe to tackle high drug prices. But they divide over whether to take savings from that to move to a 鈥楳edicare for All鈥 insurance system, enhance the current Medicare program or strengthen benefits under the Affordable Care Act.
By Julie Rovner -
CVS and Walgreens Have Wasted More Vaccine Doses Than Most States Combined
More than 200,000 doses of covid vaccine have gone to waste since December, KHN has learned. Two national pharmacy chains account for most of it.
By Joshua Eaton and Rachana Pradhan -
Detecting Rare Blood Clots Was a Win, But US Vaccine Safety System Still Has Gaps
With some 100 million Americans fully vaccinated, the U.S. is relying on a patchwork network of vaccine monitoring systems that lack the breadth and depth of large, population-based programs, experts said.